OBALON THERAPEUTICS INC Business Finance Contracts & Agreements
61 Contracts & Agreements
- Credit Agreements (5 contracts)
- Equity Distribution Agreements (1)
- Exchange Agreements (1)
- Guarantee Agreements (1)
- Investor Rights Agreements (1)
- Loan Agreements (4)
- Note Agreements (1)
- Purchase Agreements (6)
- Registration Rights Agreements (2)
- Stock Agreements (4)
- Underwriting Agreements (6)
- Warrant Agreements (29)
- Form of Warrant Exercise Agreement, dated November 21, 2023, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on November 29, 2023)
- Form of New Warrant (Filed With SEC on November 29, 2023)
- Form of Placement Agent Warrant (Filed With SEC on October 5, 2023)
- Form of Common Warrant (Filed With SEC on September 27, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on September 12, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on September 12, 2023)
- Form of Common Warrant (Filed With SEC on September 12, 2023)
- Form of Securities Purchase Agreement, dated April 20, 2023, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on April 26, 2023)
- Form of Pre-funded Warrant (Filed With SEC on April 26, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on April 26, 2023)
- Underwriting Agreement, dated February 6, 2023, by and between ReShape Lifesciences Inc. and Maxim Group LLC (Filed With SEC on February 10, 2023)
- Form of Common Warrant (Filed With SEC on February 3, 2023)
- Form of Warrant Agency Agreement between ReShape and American Stock Transfer & Trust Company, LLC (Filed With SEC on January 27, 2023)
- Form of Underwriters Warrant (Filed With SEC on January 27, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on January 27, 2023)
- Form of Common Warrant (Filed With SEC on January 27, 2023)
- Form of Underwriting Agreement (Filed With SEC on January 27, 2023)
- Form of Warrant Amendment Agreement, dated November 8, 2022, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on November 14, 2022)
- Form of Securities Purchase Agreement, dated November 8, 2022, by and between ReShape Lifesciences Inc. and the Investor (Filed With SEC on November 14, 2022)
- Form of Pre-funded Warrant (Filed With SEC on November 14, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on November 14, 2022)
- Warrant Exercise Agreement, dated June 16, 2022, by and among ReShape Lifesciences Inc. and the investor party thereto (Filed With SEC on June 23, 2022)
- Form of New Warrant (Filed With SEC on June 23, 2022)
- Form of Exchange Agreement, dated July 16, 2021, by and among ReShape Lifesciences Inc. and the investors party thereto (Filed With SEC on July 19, 2021)
- Form of New Warrant (Filed With SEC on July 19, 2021)
- Warrant Exercise Agreement, dated June 28, 2021, by and among ReShape Lifesciences Inc. and the purchasers party thereto (Filed With SEC on July 2, 2021)
- Form of New Warrant (Filed With SEC on July 2, 2021)
- Fourth Amendment to Credit Agreement, dated January 19, 2021, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)
- Credit Facility Agreement, dated as of January 19, 2021, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)
- Third Amendment to Credit Agreement, dated December 16, 2020, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)
- Second Amendment to Credit Agreement, dated September 14, 2020, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)
- Guarantee and Collateral Agreement, dated March 25, 2020, by and between ReShape Lifesciences Inc., ReShape Medical LLC and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)
- Credit Agreement, dated March 25, 2020, by and between ReShape Lifesciences Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on March 30, 2021)
- Form of Warrant (Filed With SEC on August 14, 2020)
- Form of Stock Option Agreement (Cash Settlement) (Filed With SEC on July 30, 2020)
- Promissory Note, dated as of April 22, 2020 by and between Obalon Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on April 27, 2020)
- Registration Rights Agreement, dated February 5, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on February 7, 2020)
- Purchase Agreement, dated February 5, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on February 7, 2020)
- Underwriting Agreement, entered into by Obalon Therapeutics, Inc. on August 1, 2019 with A.G.P./Alliance Global Partners (Filed With SEC on August 6, 2019)
- Form of Warrant Agent Agreement between Obalon Therapeutics, Inc. and American Stock Transfer & Trust Company, LLC (Filed With SEC on August 1, 2019)